ticker
stringlengths 2
5
| disease
stringlengths 3
196
| stage
stringclasses 15
values | date
stringlengths 19
19
| catalyst
stringlengths 18
760
| label
int64 -1
1
|
|---|---|---|---|---|---|
ABBV
|
Systemic Lupus Erythematosus (SLE)
|
Phase 2
|
2023-05-31 00:00:00
|
Phase 2 data reported that trial met primary endpoint, noted May 31, 2023.
| 0 |
SLS
|
Ovarian cancer
|
Phase 1/2
|
2022-11-10 00:00:00
|
Phase 1/2 data noted a Median Overall Survival (OS) of 18.4 months compared to 13.8 months, noted November 10, 2022.
| 0 |
BGNE
|
Non-small cell lung cancer (NSCLC)
|
Phase 3
|
2021-04-12 00:00:00
|
Phase 3 trial met primary endpoint of overall survival - November 17, 2020. Data presented at AACR meeting April 12, 2021. ORR 21.9% vs 7.0% for docetaxel; PFS 23.3% vs 5.7% in docetaxel arm; OS 17.2 months vs to 11.9 months in the docetaxel arm.
| 1 |
PFE
|
HR+/HER2- advanced breast cancer in men
|
Approved
|
2019-04-04 00:00:00
|
FDA approval of sNDA announced April 4, 2019.
| 1 |
LCTX
|
Geographic atrophy (GA)
|
Phase 1/2
|
2023-10-05 00:00:00
|
Phase 1/2 results presented at EURETINA Congress reported that 5 patients had an average of 4.4 letter BCVA gain by 3 months and 12.8 letter BCVA gain by 1 year compared to baseline, noted October 5, 2023.
| 1 |
MRK
|
Von Hippel-Lindau Syndrome
|
Approved
|
2021-08-13 00:00:00
|
FDA approval announced August 13, 2021.
| 1 |
TAK
|
Relapsed/Refractory Multiple Myeloma
|
Phase 1/2
|
2022-12-12 00:00:00
|
Phase 1/2 final data reported that treatment significantly improved the degranulation of NK cells after 4-hour stimulation with K562 or PMA/Ionomycin, noted December 12, 2022.
| 1 |
AMYT
|
Acromegaly
|
Approved
|
2020-06-26 00:00:00
|
FDA approval announced June 26, 2020.
| 1 |
INCY
|
Anal cancer
|
Phase 2
|
2020-09-18 00:00:00
|
Phase 2 data noted objective response rate of 14% and disease control rate of 49%.
| 0 |
NVO
|
Type 2 Diabetes
|
Approved
|
2022-03-28 00:00:00
|
Approved March 28, 2022.
| 1 |
BHVN
|
Spinal Muscular Atrophy (SMA)
|
Phase 3
|
2023-09-14 00:00:00
|
Phase 3 trial to continue dosing, noted November 9, 2022. Phase 3 dosing completed, noted September 14, 2023.
| 0 |
GKOS
|
Dry Eye Disease (DED)
|
Phase 2a
|
2023-01-10 00:00:00
|
Phase 2a outcomes for GLK-301 demonstrated improvement in the quality of tear film, noted January 10, 2023.
| 1 |
DERM
|
Papulopustular rosacea
|
Phase 3
|
2023-07-11 00:00:00
|
Phase 3 topline data achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant safety issues. NDA filing due in 2H 2023.
| 1 |
MRK
|
Advanced unresectable or metastatic gastric (GEJ) adenocarcinoma
|
Phase 3
|
2023-02-16 00:00:00
|
Phase 3 trial combination data showed statistically significant improvements in progression-free survival and objective response rate, noted February 16, 2023.
| 1 |
MGNX
|
Metastatic breast cancer
|
Approved
|
2021-09-07 00:00:00
|
Final overall survival data did not demonstrate MARGENZA plus chemotherapy had a statistically significant advantage compared to trastuzumab plus chemotherapy; September 7, 2021.
| 1 |
IRWD
|
Chronic idiopathic constipation (CIC)
|
Approved
|
2017-01-26 00:00:00
|
sNDA approval announced January 26, 2017.
| 1 |
ATXS
|
Hereditary angioedema (HAE), healthy volunteers
|
Phase 1a
|
2023-02-24 00:00:00
|
Phase 1a trial data reported a half-life of 117 days, supporting dosing every three months or less, noted February 24, 2023.
| 0 |
ARWR
|
Homozygous Familial Hypercholesterolemia (HoFH)
|
Phase 2
|
2023-05-23 00:00:00
|
Phase 2 interim data from two doses reported mean reductions in LDL-C (Martin-Hopkins) of 48.1% and 44.0%, mean reductions in ApoB of 39.2% and 34.5%, mean reductions in ANGPTL3 of 82.7% and 80.1%, noted May 23, 2023.
| 1 |
BLRX
|
Consolidation treatment for AML cancer patients
|
Phase 2b
|
2020-11-23 00:00:00
|
Phase 2b trial did not meet primary endpoint - November 23, 2020.
| 1 |
LLY
|
Cluster headache
|
Approved
|
2019-06-04 00:00:00
|
FDA Approval announced June 4, 2019.
| 1 |
INCY
|
Vitiligo
|
Approved
|
2022-07-19 00:00:00
|
Approved July 19, 2022.
| 1 |
VIRX
|
Epstein Barr Virus-associated cancers
|
Phase 2
|
2023-10-04 00:00:00
|
Phase 2 trial demonstrated overall and complete response rates of 40%; follow-up from the Phase 1b/2 study demonstrated median duration of response extended to 17.3 months, noted October 4, 2023.
| 1 |
RETA
|
Friedreich’s ataxia (FA)
|
Approved
|
2023-06-28 00:00:00
|
PAS approved June 28, 2023.
| 1 |
NEXI
|
Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome (MDS) after allogeneic HCT
|
Phase 1/2
|
2023-06-05 00:00:00
|
Phase 1/2 clinical results expected to be shared at ASCO showed that treatment was well tolerated with a favorable safety profile, including no grade > 3 treatment related events as of May 2023, noted on June 5, 2023.
| 1 |
ATXI
|
Postoperative pain following bunionectomy surgery
|
CRL
|
2022-02-15 00:00:00
|
FDA AdCom Meeting resulted in a 8-14 vote against the question that the application showed that benefits outweighs the risks, noted February 15, 2022.
| 1 |
MRK
|
Pneumococcal disease
|
Approved
|
2021-07-16 00:00:00
|
FDA approval announced July 16, 2021.
| 1 |
BNTX
|
COVID-19 Vaccine (Booster)
|
Phase 1/2
|
2022-05-23 00:00:00
|
Phase 1/2/3 booster trial in children reported that a 80.3% vaccine efficacy, noted May 23, 2022.
| 0 |
PFE
|
Transthyretin amyloid cardiomyopathy (ATTR-CM)
|
Approved
|
2019-05-06 00:00:00
|
FDA approval announced May 6, 2019.
| 1 |
TGTX
|
Follicular lymphoma (FL)
|
Approved
|
2021-02-05 00:00:00
|
FDA approval announced February 5, 2021.
| 1 |
AMGN
|
Atopic dermatitis
|
Phase 2
|
2021-10-02 00:00:00
|
Phase 2 study met the primary objective, showing statistically greater improvements in EASI score at 16 weeks with all four subcutaneous doses compared with placebo, noted October 2, 2021
| 1 |
AZN
|
Non-small cell lung cancer (NSCLC)
|
Approved
|
2022-11-11 00:00:00
|
Approved November 11, 2022.
| 1 |
LYRA
|
Chronic rhinosinusitis / Chronic Sinusitis
|
Phase 2
|
2022-09-10 00:00:00
|
Additional Phase 2 results data presented at ARS demonstrated that significantly more patients at baseline improved to mild/no symptoms at week 24 after treatment compared to control, noted September 10, 2022.
| 1 |
PFE
|
Non-metastatic high risk hormone-sensitive prostate cancer
|
Approved
|
2018-07-13 00:00:00
|
FDA approval announced July 13, 2018.
| 1 |
CBAY
|
Primary biliary cholangitis (PBC)
|
Phase 3
|
2023-09-07 00:00:00
|
Phase 3 registration trial achieved the primary and all key secondary endpoints, noted on September 7, 2023.
| 1 |
ACAD
|
Adjunctive Treatment in Patients With Major Depressive Disorder
|
Phase 3
|
2020-07-20 00:00:00
|
Phase 3 trial did not meet primary endpoint - July 20, 2020.
| 1 |
JNJ
|
Diabetic Kidney Disease
|
Approved
|
2019-09-30 00:00:00
|
FDA Approval announced September 30, 2019.
| 1 |
ICPT
|
Primary biliary cirrhosis (PBC)
|
Approved
|
2016-05-27 00:00:00
|
Approved May 27 2016.
| 1 |
OBSV
|
Uterine fibroids
|
Phase 3
|
2021-10-20 00:00:00
|
Phase 3 data reported once daily treatment without ABT reduced uterine volume by 39% after 24 weeks. However, co-administration of hormonal ABT after 24 weeks counteracted the uterine volume reducing effects at 52 weeks, noted October 20, 2021.
| 1 |
XFOR
|
Severe Congenital Neutropenia (SCN)
|
Phase 2
|
2023-08-10 00:00:00
|
Phase 2 data reported that three participants receiving G-CSF and once-daily oral mavorixafor showing robust increases in ANC, maintenance of ANC levels in the normal range, and the ability to reduce G-CSF dose earlier than anticipated, noted August 10, 2023.
| 1 |
MBRX
|
Acute myeloid leukemia (AML)
|
Phase 1b
|
2023-05-02 00:00:00
|
Phase 1b data noting one CR and determined that the first cohort dose as safe, noted May 2, 2023.
| 0 |
CPRX
|
Pediatric Lambert-Eaton myasthenic syndrome (LEMS)
|
Approved
|
2022-09-29 00:00:00
|
sNDA approved September 29, 2022.
| 1 |
BCRX
|
Acute Influenza
|
Approved
|
2014-12-22 00:00:00
|
Approved December 22, 2014.
| 1 |
KTRA
|
Newly diagnosed MGMT-unmethylated Glioblastoma Multiform (GBM)
|
Phase 2
|
2023-09-23 00:00:00
|
Additional Phase 2 case study data to be presented at EANO reported that a patient was tumor-free and has survived more than four years as of the last follow-up in March 2023, and another patient had discontinued treatment and a new lesion was found, noted September 23, 2023.
| 1 |
JNJ
|
Psoriatic arthritis (PsA)
|
Approved
|
2017-10-20 00:00:00
|
Approval announced October 20, 2017.
| 1 |
EWTX
|
Becker muscular dystrophy (BMD)
|
Phase 1b
|
2023-06-26 00:00:00
|
Phase 1b 12-month study supported the hypothesis that a reduction in contraction-induced muscle damage in muscular dystrophies, associated with administration, has the potential to preserve and improve muscle function while preventing disease progression in dystrophinopathies, noted June 26, 2023.
| 1 |
LLY
|
Second-line hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer and HR+, HER2- breast cancer
|
Approved
|
2017-10-04 00:00:00
|
Approved October 4, 2017.
| 1 |
AXSM
|
Migraine
|
CRL
|
2022-05-02 00:00:00
|
CRL announced May 2, 2022.
| 0 |
ETON
|
Injectable hospital product
|
Approved
|
2021-06-15 00:00:00
|
FDA approval announced June 15, 2021.
| 1 |
SABS
|
COVID-19
|
Phase 3
|
2023-04-26 00:00:00
|
Phase 3 trial demonstrated benefit in sustained symptom resolution in study participants with COVID-19 caused by Omicron as compared to participants who received a monoclonal antibody combination, REGEN-COV. Specifically, 66% of participants treated with SAB-185 reached full symptom resolution for at least 4 consecutive days by Day 28, while only 50% of participants on REGEN-COV met this endpoint, and the median time to symptom resolution for at least 4 consecutive days was 7 days shorter for SAB-185, noted April 26, 2023.
| 1 |
LLY
|
Metastatic colorectal cancer
|
Approved
|
2021-09-28 00:00:00
|
Approved September 28, 2021.
| 1 |
HALO
|
Amyloidosis
|
Approved
|
2021-01-15 00:00:00
|
FDA approval announced January 15, 2021.
| 1 |
IMTX
|
Solid tumors
|
Phase 1b
|
2023-10-24 00:00:00
|
FDA Granted RMAT on October 24, 2023.
| 0 |
LLY
|
Non-small cell lung cancer
|
Approved
|
2020-05-29 00:00:00
|
FDA Approval announced May 29, 2020.
| 1 |
MRNA
|
Ovarian cancer
|
Phase 2
|
2021-08-05 00:00:00
|
Development has been discontinued - noted August 5, 2021.
| -1 |
AUTL
|
T-cell lymphoma
|
Phase 1
|
2023-06-16 00:00:00
|
Additional data presented at the ICML showed that all 4 patients at the highest dose in the study achieved a response and 2/4 remained in a complete metabolic response beyond 12 months, noted June 16, 2024.
| 1 |
MBRX
|
Soft tissue sarcoma lung metastases
|
Phase 1/2
|
2022-07-28 00:00:00
|
Preliminary Phase 1b data reported that treatment demonstrated clinical activity, defined as stable disease or better, noted July 28, 2022.
| 1 |
TAK
|
Colorectal cancer
|
Phase 3
|
2022-09-08 00:00:00
|
Phase 3 data demonstrated that treatment reduced the risk of death by 34% in metastatic colorectal cancer , and Increased disease control with risk of disease progression or death reduced by 68%, noted September 8, 2022
| 1 |
DRUG
|
Dravet Syndrome
|
Phase 1/2
|
2023-08-08 00:00:00
|
Additional Phase 1/2 cohort 4 data reported an increase in central delta power and robust reduction in central alpha and beta power in active group, as previously reported for Anti-Epileptic Drugs (AEDs) in healthy individuals, noted August 8, 2023.
| 1 |
GMAB
|
Squamous cell carcinoma of the head and neck (SCCHN)
|
Phase 2
|
2023-04-17 00:00:00
|
Phase 2 interim results presented at AACR reported a confirmed ORR of 40%, with one complete response and 5 partial responses, noted April 17, 2023.
| 1 |
RHHBY
|
Breast Cancer
|
Phase 2
|
2022-05-26 00:00:00
|
Phase 2 final analysis presented at ASCO reported that greater suppression of Ki67 was observed at surgery with giredestrant + P, with an ORR of 50%, noted May 26, 2022.
| 1 |
CHRS
|
NSCLC neoadjuvant setting
|
Phase 3
|
2023-06-03 00:00:00
|
Phase 3 Interim event-free survival (EFS) analysis presented at ASCO reported that MPR and pCR rates per BIPR were higher in the toripalimab arm, 48.5% vs 8.4% and 24.8% vs 1.0%, respectively, noted June 3, 2023.
| 1 |
KYMR
|
Peripheral T-cell Lymphoma (PTCL)
|
Phase 1a
|
2023-06-14 00:00:00
|
Phase 1a data continue to demonstrate robust dose-dependent target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose limiting toxicities (DLTs) observed, noted June 14, 2023.
| 1 |
LLY
|
RET Fusion-Positive Solid Tumors
|
Approved
|
2022-09-21 00:00:00
|
Approved September 21, 2022.
| 1 |
NRIX
|
Cellular therapy
|
Phase 1
|
2022-11-10 00:00:00
|
Phase 1 clinical update reported increases the antitumor activity of the transferred T cells when compared to ACT alone, noted November 10, 2022.
| 0 |
REVB
|
H3N2 Influenza
|
Phase 2b
|
2022-03-30 00:00:00
|
Phase 2b trial did not meet primary efficacy endpoint, noted March 30, 2022.
| 1 |
IGMS
|
Hepatocellular carcinoma (HCC)
|
Phase 1/2
|
2023-09-05 00:00:00
|
Phase 1b/2 interim data reported complete response was recorded in 1 patient, partial response in 2 patients, and stable disease in 2 patients, noted September 5, 2023.
| 0 |
BIIB
|
Friedreich’s ataxia (FA)
|
Approved
|
2023-06-28 00:00:00
|
PAS approved June 28, 2023.
| 1 |
LQDA
|
Pulmonary arterial hypertension
|
Approved
|
2021-11-08 00:00:00
|
Tentative approval November 8, 2021. Final approval due in October 2022 or earlier upon resolution of on-going litigation.
| 1 |
LLY
|
Type 2 diabetes
|
Phase 3
|
2022-06-04 00:00:00
|
Phase 3 data results presented at ADA's 82nd Scientific Sessions® and simultaneously published in the New England Journal of Medicine demonstrate A1C reductions of up to 1.5% for Trulicity compared to placebo in this underserved population.
| 1 |
ARQT
|
Seborrheic dermatitis
|
Phase 3
|
2022-09-09 00:00:00
|
Additional Phase 3 data presented at EADV reported that more than 60% of patients treated with roflumilast foam achieved an itch response at Week 8, noted September 9, 2022.
| 1 |
TSHA
|
Giant axonal neuropathy (GAN)
|
Phase 1/2
|
2022-01-31 00:00:00
|
Phase 1/2 data demonstrated that dosing was safe and well-tolerated supported by 53 patient-years of clinical data, efficacy data for high dose cohort showed clinically and statistically significant improvement by Year 1 compared to natural history. Biopsy data in (5/6) patient samples analyzed to date confirmed active regeneration of nerve fibers, noted January 31, 2022.
| 1 |
CAPR
|
Myocardial infarction (heart attack)
|
Phase 2
|
2017-05-12 00:00:00
|
Phase 2 data released May 12, 2017 - primary endpoint unlikely to be met.
| 0 |
CRDF
|
Prostate cancer
|
Phase 2
|
2021-02-11 00:00:00
|
Phase 2 data disease control rate at 12 weeks of 35%.
| 0 |
MTNB
|
Cryptococcal meningitis
|
Phase 1/2
|
2022-10-21 00:00:00
|
Phase 1/2 cohort 4 data reported that CSF yeast clearance rate exceeded the prespecified primary endpoint, with an interim survival currently 90%, while the survival rate at Week 2 was 95%, noted October 21, 2022.
| 0 |
RVNC
|
Upper facial lines
|
Phase 2
|
2020-12-17 00:00:00
|
Efficacy of none or mild wrinkle severity seen in greater than 92% of subjects after four weeks.
| 0 |
LLY
|
Psoriasis
|
Phase 3
|
2020-07-17 00:00:00
|
Phase 3 trial met primary and all key secondary endpoints vs placebo at Week 16 and all key secondary endpoints versus Cosentyx (secukinumab) at Week 16 and Week 52 - July 17, 2020.
| 0 |
IPHA
|
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
|
Phase 2
|
2023-10-16 00:00:00
|
Phase 2 results reported that D+M 1 partial response (PR) was recorded and stable disease (SD) was observed in 11 pts (26%), noted October 16, 2023.
| 1 |
IRWD
|
Hyperuricemia associated with gout
|
Approved
|
2017-08-21 00:00:00
|
Approval announced August 21, 2017.
| 1 |
MRK
|
Unresectable hepatocellular carcinoma (uHCC)
|
Phase 3
|
2022-09-10 00:00:00
|
Phase 3 trial data was not statistically significant, noted August 3, 2022. Phase 3 data presented at ESMO showed that there was a trend toward improvement for one of the study's dual primary endpoints, overall survival (OS), for patients treated; however, the results did not meet statistical significance per the pre-specified statistical plan. The median OS was 21.2 months for combination and 19.0 months monotherapy, September 10, 2022.
| 1 |
GLPG
|
Ulcerative Colitis
|
Phase 2
|
2021-07-14 00:00:00
|
Phase 2 data released July 14, 2021. No differentiation from placebo.
| -1 |
LLY
|
Heart failure with preserved Ejection Fraction (HFpEF)
|
Approved
|
2022-02-24 00:00:00
|
Approved February 24, 2022.
| 1 |
PHVS
|
Hereditary angioedema - prophylactic use
|
Phase 1
|
2022-11-10 00:00:00
|
Phase 1 PK data reported that food intake did not have significant effects on the time to reach therapeutic exposure, with no server or serious treatment-emergent adverse events, noted November 10, 2022.
| 1 |
VBIV
|
Hepatitis B vaccine
|
Approved
|
2021-12-01 00:00:00
|
Approved December 1, 2021.
| 1 |
ENTA
|
Hepatitis B
|
Phase 1
|
2021-11-18 00:00:00
|
Development discontinued, noted November 18, 2021.
| -1 |
RARE
|
Tumor-induced osteomalacia (TIO)
|
Approved
|
2020-06-18 00:00:00
|
FDA Approval announced June 18, 2020.
| 1 |
RHHBY
|
Macular edema due to RVO
|
Approved
|
2023-10-27 00:00:00
|
Approved October 27, 2023.
| 1 |
PFE
|
Cancer pain
|
Phase 3
|
2021-07-28 00:00:00
|
Phase 3 trial met primary endpoint - July 2021.
| 0 |
ABBV
|
Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
|
Approved
|
2014-02-12 00:00:00
|
Approved February 12, 2014.
| 1 |
PFE
|
Vaso-occlusive crisis of sickle cell disease
|
Phase 3
|
2019-08-02 00:00:00
|
Phase 3 data failed to meet endpoints - August 2, 2019.
| 1 |
ACOR
|
Post stroke deficits
|
Phase 3
|
2016-11-21 00:00:00
|
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
| 1 |
PFE
|
Sickle cell disease (SCD)
|
Phase 2/3
|
2023-11-02 00:00:00
|
Phase 2/3 data from ASH abstract reported that safety data showed GBT021601 was well tolerated. For 27 patients with VOC at baseline, the baseline annualized VOC rate was 2.30, noted November 2, 2023.
| 1 |
CING
|
Healthy volunteers in fed and fasted states
|
Phase 1
|
2023-02-23 00:00:00
|
Phase 1 data demonstrated that CTx-1301 can be taken with or without food, noted February 23, 2023.
| 1 |
BMY
|
Relapsed/Refractory Multiple Myeloma (RRMM)
|
Phase 1
|
2022-12-12 00:00:00
|
Phase 1 preliminary results reported ORR was 39.6%, with 2 (2.0%) stringent complete responses, 3 (3.0%) complete responses, 18 (17.8%) very good partial responses, and 17 (16.8%) partial responses, noted December 12, 2022.
| 0 |
UTHR
|
Pulmonary hypertension associated with interstitial lung disease (PH-ILD) (WHO Group 3)
|
Approved
|
2021-04-01 00:00:00
|
FDA approval announced April 1, 2021.
| 1 |
TPST
|
Hepatocellular Carcinoma (HCC), Solid tumors
|
Phase 1/2
|
2023-04-17 00:00:00
|
Additional biomarker data presented at AACR reported on-target changes in gene signatures in the peripheral blood that were dependent upon drug exposure levels, noted April 17, 2023.
| 1 |
VERU
|
Benign prostatic hyperplasia (BPH)
|
Approved
|
2021-12-13 00:00:00
|
Approved December 13, 2021.
| 1 |
PFE
|
Complicated Intra-abdominal Infection and Hosptial Acquired Pneumonia
|
Phase 3
|
2023-06-01 00:00:00
|
Phase 3 data reported that the cure rate in the intention to treat (ITT) analysis set was 76.4% for the ATM-AVI ± MTZ treatment arm vs 74.0% for the MER ± COL treatment arm, with a treatment difference of 2.4%, noted June 1, 2023.
| 1 |
BLPH
|
Pulmonary Arterial Hypertension (PAH)
|
Phase 3
|
2018-08-07 00:00:00
|
Phase 3 trial stopped due to futility - August 7, 2018.
| -1 |
DRRX
|
Psoriasis
|
Phase 2a
|
2020-01-02 00:00:00
|
Phase 2 top-line data did not meet endpoints - January 2, 2020.
| 1 |
ABEO
|
Sanfilippo syndrome type B (MPS IIIB)
|
Phase 1/2
|
2021-02-12 00:00:00
|
Phase 1/2 updated data announced February 12, 2021.
| 0 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.